Syndax eliminates Chief Medical Officer role; Dr. Catherine Madigan departs

Syndax Pharmaceuticals Inc

CMO Catherine Madigan, M.D. ceased employment effective December 20, 2024, after position eliminated.
Severance compensation consistent with service agreement terms (Exhibits 10.24, 10.25 to 2023 10-K).
No replacement appointed; company restructures clinical leadership without a CMO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.